Drug Profile
Vecabrutinib - Viracta Therapeutics
Alternative Names: SNS 062; SNS-062-succinate; Vecabrutinib succinate - Viracta TherapeuticsLatest Information Update: 07 Apr 2023
Price :
$50
*
At a glance
- Originator Biogen Idec; Sunesis Pharmaceuticals
- Developer Biogen; Viracta Therapeutics
- Class Amides; Amines; Aniline compounds; Antineoplastics; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Piperidines; Pyrimidines; Small molecules; Succinates
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Graft-versus-host disease
- Discontinued Haematological malignancies
Most Recent Events
- 07 Apr 2023 Preclinical trials in Cancer in USA (PO) (Viracta Therapeutics pipeline, April 2023)
- 07 Apr 2023 Preclinical trials in Unspecified in USA (PO) (Viracta Therapeutics pipeline, April 2023)
- 13 Dec 2021 Pharmacodynamics data from a preclinical trial in Haematological malignancies and Graft-versus-host disease presented at the American Society of Hematology Annual Meeting (ASH-2021)